Skip to content

This website is intended for UK healthcare professionals only

This is a promotional website developed by AstraZeneca

The prescribing information can be found at the bottom of the page

bars
NEW: ADAURA 5yr OS DATA AVAILABLE

Welcome to TAGRISSO® (osimertinib) Connect

This is a promotional website developed by AstraZeneca, which will discuss AstraZeneca products.

Osimertinib as a monotherapy is indicated for:

  • The adjuvant treatment after complete tumour resection in adult patients with stage IB-IIIA non-small cell lung cancer (NSCLC) whose tumours have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations
  • The first-line treatment of adult patients with locally advanced or metastatic NSCLC with activating EGFR mutations
  • The treatment of adult patients with locally advanced or metastatic EGFR T790M mutation-positive NSCLC

On this site you will find information and a range of materials to support you in the management of patients with EGFR mutation-positive non-small cell lung cancer (NSCLC).